Product Overview
OFEV® is an anti-fibrotic medicine and contains the active ingredient nintedanib. It is used in adults for the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.1
The 'Resources' tab in the 'Quick links' section redirects to a Boehringer Ingelheim website that provides more information about OFEV®, IPF and other chronic fibrosing ILDs.
Product Key Facts
Indications
In adults for the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
Active ingredient
Nintedanib esilate
Legal category
Prescription only medicine
Doses and frequency
The recommended dose is 150 mg nintedanib twice daily administered approximately 12 hours apart. 100 mg twice daily dose is recommended to be used in patients who do not tolerate the 150 mg twice daily dose. Please refer to the Summary of Product Characteristics for further information on OFEV®
Route of administration
Oral
Pharmaceutical form
Soft capsule
Contraindications
- Pregnancy
- Hypersensitivity to nintedanib, to peanut or soya, or to any of the excipients
Adverse Events
In clinical trials and during the post-marketing experience, the most frequently reported adverse reactions associated with the use of nintedanib included diarrhoea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased. Please refer to the OFEV® Summary of Product Characteristics for more information on adverse events
Reference
- OFEV® 100 mg and 150 mg soft capsules Summary of Product Characteristics. Boehringer Ingelheim.
PC-GB-110730 V2 | March 2025